Navigation Links
Nile Therapeutics to Transition to OTCQB Marketplace

SAN MATEO, Calif., May 11, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (NASDAQ: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the Company's securities will cease trading on The Nasdaq Capital Market effective with the open of business on May 12, 2011.  The Company expects its common stock to begin trading under the "NLTX" symbol on the OTCQB Marketplace following the suspension of trading on the Nasdaq Capital Market.

As previously disclosed, on November 30, 2010, the Company was notified by The NASDAQ Stock Market ("NASDAQ") that its securities were subject to delisting based upon the Company's failure to satisfy NASDAQ's minimum $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2).  The Company subsequently attended a hearing before the NASDAQ Listing Qualifications Panel (the "Panel") at which it presented its plan to regain compliance with the minimum bid price requirement by May 31, 2011, one component of which consisted of effecting a reverse stock split.  On March 1, 2011, the Panel granted the Company's request for an extension to remain listed on NASDAQ, subject to the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by May 31, 2011 and demonstrating compliance with all other applicable listing standards as of such date.  On May 10, 2011, the Company informed NASDAQ that it had determined not to proceed with a reverse stock split prior to May 31, 2011.  Accordingly, on May 10, 2011, the Company was notified by NASDAQ that trading in its securities on would be suspended on The Nasdaq Capital Market as of the open of business on May 12, 2011, with formal delisting to follow.

Operated by OTC Markets Group Inc., the OTCQB is a market tier for OTC traded companies that are registered and reporting with the Securities and Exchange Commission. The Company expects its common stock will continue to trade under the "NLTX" symbol on the computerized OTCQB system. Investors will be able to view Level II Real Time stock quotes for Nile at

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's transition from The Nasdaq Capital Market to the OTCQB Marketplace, including the timing of trading of and the prospects for a market developing for Nile's securities on the OTCQB, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with the Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Cell Therapeutics Retires 7.5% Convertible Senior Notes
6. Talecris Biotherapeutics Announces First Quarter 2011 Results
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
11. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... , ... November 24, 2015 , ... This fall, global ... competitive events in five states to develop and pitch their BIG ideas to improve ... each state are competing for votes to win the title of SAP's Teen Innovator, ...
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):